Vor Biopharma (VOR) Cash & Equivalents (2020 - 2026)

Vor Biopharma (VOR) has 7 years of Cash & Equivalents data on file, last reported at $169.9 million in Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $169.9 million, up 239.43% year-over-year; the trailing twelve-month figure through Mar 2026 was $169.9 million (up 239.43% YoY), and the FY2025 annual result was $396.5 million, up 383.82% from the prior year.
• Cash & Equivalents fell to $169.9 million in Q1 2026 per VOR's latest filing, from $396.5 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $396.5 million in Q4 2025 and troughed at $31.4 million in Q4 2023.
• A 5-year average of $96.8 million and a median of $60.8 million in 2022 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2022 and 2025: Cash & Equivalents tumbled 65.71% in 2022, then jumped 383.82% in 2025.
• A 5-year view of Cash & Equivalents shows it stood at $57.7 million in 2022, then sank by 45.66% to $31.4 million in 2023, then surged by 161.32% to $81.9 million in 2024, then jumped by 383.82% to $396.5 million in 2025, then plunged by 57.16% to $169.9 million in 2026.
• Business Quant data shows VOR's Cash & Equivalents at $169.9 million in Q1 2026, $396.5 million in Q4 2025, and $160.5 million in Q3 2025.